SGLT2 inhibitors and 30-day readmission in critically ill adults: A multicentre observational study
Published
June 19, 2026
Paper ID
PAP-000094
Status
Published
DOI
10.65712/tmj.test000352
Advance Services
Abstract
Background: Guidelines make only a weak recommendation on SGLT2 inhibitors. Methods: Eligible participants were critically ill adults. Results: 30-day readmission occurred in 10% of the intervention group versus 23% of controls. The adjusted odds ratio was 0.73 (95% CI 0.49 to 0.79). Conclusion: Residual confounding cannot be excluded.
Introduction
Practice around SGLT2 inhibitors varies widely between centres. 30-day readmission remains a leading cause of avoidable harm among critically ill adults.
The cost of 30-day readmission to health systems is substantial.
Materials and Methods
The primary outcome was 30-day readmission, assessed blind to allocation. Analyses were adjusted for age, sex and baseline severity.
We conducted a multicentre observational study across 14 centres between 2015 and 2021. Eligible participants were critically ill adults. We conducted a multicentre observational study across 6 centres between 2020 and 2023.
Results
Serious adverse events were rare and similar between groups.
| Group | n | Events | Rate % |
|---|---|---|---|
| Age ≥ 65 | 269 | 47 | 27.6 |
| Centre A | 91 | 28 | 31.8 |
| Intervention | 156 | 111 | 32.9 |
| Centre A | 775 | 27 | 6.8 |
| Centre A | 257 | 45 | 36.7 |
| Male | 240 | 69 | 32.4 |
| Centre A | 56 | 119 | 14.3 |
Values are n (%) unless stated otherwise.

Shown for critically ill adults; error bars are 95% confidence intervals.
Effects were consistent across prespecified subgroups. 30-day readmission occurred in 20% of the intervention group versus 32% of controls. 30-day readmission occurred in 12% of the intervention group versus 16% of controls. 30-day readmission occurred in 8% of the intervention group versus 21% of controls.
1530 participants were included (median age 70 years). 30-day readmission occurred in 7% of the intervention group versus 14% of controls. Serious adverse events were rare and similar between groups.
Discussion
Residual confounding cannot be excluded. These findings suggest that SGLT2 inhibitors is associated with better 30-day readmission in critically ill adults.
Strengths include the sample size and blinded outcome assessment.
Residual confounding cannot be excluded. These findings suggest that SGLT2 inhibitors is associated with better 30-day readmission in critically ill adults.
Residual confounding cannot be excluded. Implementation will depend on staffing, cost and local protocols. Strengths include the sample size and blinded outcome assessment.
Conclusions
SGLT2 inhibitors merits wider use for critically ill adults to improve 30-day readmission.
References
1. Larsen H, Farouk U, et al. Home-based cardiac rehabilitation and acute kidney injury. JAMA. 2022;148(4):328-1134.
2. Tanaka H, Andersen D, et al. Nurse-led discharge planning and falls. BMJ. 2020;318(8):803-975.
3. Novak J, Okafor A, et al. An antibiotic stewardship programme and medication adherence. BMC Med. 2015;284(5):541-1626.
4. Haddad E, Volkov X, et al. Home-based cardiac rehabilitation and glycaemic control. N Engl J Med. 2017;361(2):138-1112.
5. Schmidt Z, Nakamura N, et al. Early enteral nutrition and in-hospital mortality. Diabetes Care. 2015;344(9):339-1782.
Appendices
The statistical analysis plan is in the online supplement.